Advertisement


Jenny S. Guadamuz, PhD, on Racial and Socioeconomic Disparities in Telemedicine Use Among U.S. Patients With Cancer During the COVID-19 Pandemic

2022 ASCO Annual Meeting

Advertisement

Jenny S. Guadamuz, PhD, of Flatiron Health, discusses the use of telemedicine services in community oncology clinics for patients initiating treatments for 21 common cancers during the COVID-19 pandemic. Black, uninsured, non-urban, and less affluent patients were less likely to use telemedicine services. Although telemedicine may expand access to specialty care, the proliferation of these services may widen cancer care disparities if equitable access to these services is not ensured, according to Dr. Guadamuz (Abstract 6511).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
The COVID-19 pandemic was associated with disruptions in healthcare delivery, including decreases in in-person clinical visits. As a result, many clinicians shifted to telemedicine or telehealth services to mitigate these declines in in-person care. And this was facilitated by federal and state regulations enacted early in the pandemic that expanded coverage and reimbursement for telemedicine services. There is some evidence that telemedicine uptake varied by social demographic factors, such as age and sex. However, there's been very limited evaluations of inequities in telemedicine use among patients with cancer. So in this study, we assess factors associated with telemedicine use, including the social determinants of health among patients initiating treatment for 21 common cancers at community oncology clinics during the ongoing COVID-19 pandemic. In terms of methods, this is a retrospective study that used the nationwide Flatiron health electronic health record derived database, a de-identified database. Our sample included about 27,000 patients who were required to have started their treatment, their first line of therapy, between March 2020 and November 2021 with follow up through March 2022. Our primary outcome was telemedicine use or at least one telemedicine visit within 90 days of starting their cancer treatment. This was derived with billing codes. We examined inequities by multiple social determinants of health exposures, including race, ethnicity, insurance coverage, urban role status, and area level social economic status. Overall, 16% of patients used telemedicine services. Unfortunately, there were substantial inequities in telemedicine use where black, uninsured, non-urban, and lower SES patients were all less likely to use telemedicine services. There were particularly jarring inequities across social economic status, where one in four patients living in high SES areas use these services in comparison to about 10% of patients in low SES areas. These inequities were also statistically significant even after adjusting for clinical characteristics, such as age, sex, stage, and performance status. And we also found similar patterns in sub-cohorts of patients initiating their cancer regimens for advanced stage non-small cell lung cancer, colorectal, breast, and pancreatic cancer. It is also important to note that telemedicine use peaked among patients who started their treatment early in the pandemic from March to May 2020, at about 25%, but declined to about 12% among those who did so more recently from September to November 2021. But it's important to note that most of the inequities described above persisted throughout these periods. These findings are critically important considering recent efforts to make the coverage of telemedicine services permanent instead of being tied to health and human services, public health emergency declaration for COVID-19. And also efforts increase reimbursement rates for telemedicine services by Medicare, several Medicaid programs and several private insurance. Future work should examine social determinants of health characteristics that may be associated with telemedicine inequities, including things like high speed internet access. We cannot assume that patients have the equitable infrastructure necessary to use telemedicine services. It'll also be important to determine whether telemedicine care is of high quality. For example, are there differences in the receipt of timely and guideline concordant treatment between patients who receive telemedicine services versus those who only receive in-person care? It'll be also important to determine what types of practices are providing telemedicine more equitably to their patients. We can learn from these clinics and bring it back to the rest of our network. Finally, our primary conclusion is that the proliferation of telemedicine services may widen cancer care inequities if people of color and those living in marginalized areas do not have equitable access.

Related Videos

Bladder Cancer

Shilpa Gupta, MD, on Urothelial Cancer: Defining Who Is 'Platinum-Ineligible'

Shilpa Gupta, MD, of the Cleveland Clinic Foundation, discusses an updated consensus definition for standard therapy and clinical trial eligibility for patients with metastatic urothelial cancer who are platinum-ineligible, criteria that are proposed to guide treatment recommendations for this population. This may be especially important now that the U.S. Food and Drug Administration has restricted the use of first-line pembrolizumab to those who are considered platinum-ineligible (Abstract 4577).

Prostate Cancer

Alicia K. Morgans, MD, MPH, and Ian D. Davis, PhD, MBBS, on Prostate Cancer: Updated Overall Survival Outcomes With Enzalutamide

Alicia K. Morgans, MD, MPH, of Dana-Farber Cancer Institute, and Ian D. Davis, PhD, MBBS, of Monash University and Eastern Health, discuss the latest findings from ANZUP Cancer Trials Group’s ENZAMET cooperative group trial of enzalutamide in patients with metastatic hormone-sensitive prostate cancer. The results corroborate the benefit of enzalutamide with improved overall survival, and involve some exploratory subgroup analyses (Abstract LBA5004).

Head and Neck Cancer
Supportive Care

Carryn M. Anderson, MD, on Head and Neck Cancer: New Data on Avasopasem Manganese for Oral Mucositis

Carryn M. Anderson, MD, of the University of Iowa Hospital, discusses phase III results of the ROMAN trial of avasopasem manganese for patients with severe oral mucositis who are receiving chemoradiotherapy for locally advanced, nonmetastatic head and neck cancer. Compared with placebo, avasopasem manganese improved severe oral mucositis (Abstract 6005).

Kidney Cancer
Immunotherapy

Jonathan E. Rosenberg, MD, and Thomas Powles, MD, PhD, on Renal Cell Carcinoma: New Data on Pembrolizumab Plus Axitinib vs Sunitinib as First-Line Therapy

Jonathan E. Rosenberg, MD, of Memorial Sloan Kettering Cancer Center, and Thomas Powles, MD, PhD, of Barts Health NHS Trust, Queen Mary University of London, discuss phase III findings from the KEYNOTE-426 trial, which appear to support the long-term benefit of pembrolizumab plus axitinib for first-line treatment of patients with advanced clear cell renal cell carcinoma (Abstract 4513).

Lung Cancer
Immunotherapy

Rami Manochakian, MD, on NSCLC: Clinical Implications of Findings on Nivolumab Plus Chemotherapy

Rami Manochakian, MD, of Mayo Clinic Florida, discusses the phase II findings of the NADIM II trial, which confirmed that, in terms of pathologic complete response as well as the feasibility of surgery, combining nivolumab and chemotherapy was superior to chemotherapy alone as a neoadjuvant treatment for locally advanced, resectable stage IIIA non–small cell lung cancer (Abstract 8501).

Advertisement

Advertisement




Advertisement